KALARIS THERAPEUTICS, INC.
56.50%
12,954,081
1754068
482929106
Dec 17, 2025
Feb 17, 2026, 08:14 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Srinivas Akkaraju | Individual | 56.50% | 12,954,081 | 6,000 | 12,948,081 |
| Samsara BioCapital, L.P. | Partnership | 47.90% | 10,968,234 | 0 | 10,968,234 |
| Samsara BioCapital GP, LLC | Other | 47.90% | 10,968,234 | 0 | 10,968,234 |
| Samsara Opportunity Fund, L.P. | Partnership | 8.60% | 1,979,847 | 0 | 1,979,847 |
| Samsara Opportunity Fund GP, LLC | Other | 8.60% | 1,979,847 | 0 | 1,979,847 |
Disclosure Items (4)
Common Stock, $0.0001 par value per share
KALARIS THERAPEUTICS, INC.
400 Connell Drive, Suite 5500, Berkeley Heights, NJ, 07922
Item 3 of the Statement is hereby amended and supplemented as follows: On December 18, 2025, Samsara Opportunity Fund purchased 479,847 shares of common stock from Samsara LP in a private sale for $10.42 per share, or an aggregate purchase price of $5,000,005.74. These shares represented shares held by Samsara LP for the exclusive benefit of limited partners who had redeemed their respective interests in Samsara LP and in which neither Samsara GP nor Dr. Akkaraju had any economic interest. These purchases were for cash and were funded by capital contributions from the general and limited partners of Samsara Opportunity Fund.
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of: (i) 18,702,418 shares of common stock outstanding as of November 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025; (ii) 4,200,000 shares of common stock issued in the December 2025 Private Placement as reported in the Issuer's Current Report on Form 8-K filed with the SEC on December 18, 2025; and (iii) with respect to Dr. Akkaraju, 6,000 shares of common stock issuable upon the exercise of stock options within 60 days. The Reporting Persons' ownership of the Issuer's securities consists of (i) 10,968,234 shares of common stock directly held by Samsara LP; (ii) 1,979,847 shares of common stock directly held by Samsara Opportunity Fund; and (iii) 6,000 stock options (right to buy) that are currently vested or scheduled to vest within 60 days of this filing held by Dr. Akkaraju. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. Samsara Opportunity GP is the sole general partner of Samsara Opportunity Fund and Dr. Akkaraju is the managing member of Samsara Opportunity GP. Each of Samsara Opportunity GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opportunity Fund.
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
Except as set forth herein and in Amendment No. 1, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.
Not applicable.
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13D/A filed with the SEC on December 22, 2025).